524632 — Shukra Pharmaceuticals Income Statement
0.000.00%
- IN₹922.28m
- IN₹854.02m
- IN₹745.73m
- 45
- 54
- 85
- 69
Annual income statement for Shukra Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 118 | 112 | 205 | 588 | 746 |
Cost of Revenue | |||||
Gross Profit | 88.4 | 84.3 | 101 | 135 | 301 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 118 | 114 | 193 | 553 | 572 |
Operating Profit | 0.602 | -2.25 | 12.2 | 35.3 | 174 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.71 | 0.978 | 10.2 | 44.4 | 199 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.356 | 1.88 | 7.51 | 44.1 | 185 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.356 | 1.88 | 7.51 | 44.1 | 185 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.356 | 1.88 | 7.51 | 44.1 | 185 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.01 | 0.105 | 0.249 | 6.55 | 4.23 |
Dividends per Share |